Bayer Shares Rise After First Roundup Win Since Supreme Court Ruling

A Missouri jury unanimously sided with Bayer-owned Monsanto in a case brought by three women who alleged Roundup caused their cancer, rejecting claims that the weedkiller was defectively designed and consumers were misled. The verdict is the first Roundup trial since a U.S. Supreme Court ruling curtailed lawsuits based on the absence of cancer warnings, and Bayer says the outcome signals substantial hurdles for future plaintiffs. Bayer shares rose following the decision, which analysts and investors said could strengthen the company’s position as it seeks approval for a proposed $7.25 billion settlement covering tens of thousands of pending claims. The settlement remains subject to court approval and broad support from plaintiffs; glyphosate’s cancer risks remain contested, with the International Agency for Research on Cancer classifying it as a probable human carcinogen while Bayer cites scientific studies and regulatory approvals.